Rising US health care costs have led to the creation of alternative payment and care-delivery models designed to maximize outcomes and/or minimize costs through changes in reimbursement and care delivery. The impact of these interventions in cancer care is unclear. This review was undertaken to describe the landscape of new alternative payment and care-delivery models in cancer care. In this systematic review, 22 alternative payment and/or care-delivery models in cancer care were identified. These included 6 bundled payments, 4 accountable care organizations, 9 patient-centered medical homes, and 3 other interventions. Only 12 interventions reported outcomes; the majority (n 5 7; 58%) improved value, 4 had no impact, and 1 reduced value, but only initially. Heterogeneity of outcomes precluded a meta-analysis. Despite the growth in alternative payment and delivery models in cancer, there is limited evidence to evaluate their efficacy. Cancer
INTRODUCTION
The annual cost of cancer care is particularly high and is expected to approach $173 billion by 2020, 1 which has important implications for patients, because it has been demonstrated that financial toxicity disproportionately affects patients with cancer 2 and leads to increased mortality. 3 In response to rising US health care costs, there has been increased emphasis on optimizing value, defined as health outcomes achieved per dollar spent. 4 Components of the Affordable Care Act (ACA) further catalyzed the move toward value, and the Centers for Medicare & Medicaid Services (CMS) intends to tie 50% of traditional fee-for service (FFS) payments to value by 2018. 5 The innovative care-delivery and reimbursement models rolled out in the ACA recently have been applied to cancer care and are now reported in the literature. The most widespread alternative payment models are bundled payments and accountable care organizations (ACO), each of which uses changes in reimbursement methods to incentivize improvements in care delivery. The most common new care-delivery model is the patient-centered medical home (PCMH), which is centered on enhanced care coordination to control the costs of care. Although it represents a large portion of overall health care costs, 1 cancer care largely has been excluded from initial experiments of alternative payment and care-delivery models. For example, large analyses of ACOs have not addressed cancer, 6, 7 and the largest federal bundled payment initiative excluded cancer care. 8 We conducted a systematic review to identify alternative payment and delivery models that have been tested in cancer care since passage of the ACA. The objectives of this review were to describe the landscape of alternative payment and delivery models in oncology, to evaluate the efficacy of these models on value in cancer care, and to critically examine the quality of available evidence.
METHODS
This systematic review adheres to the guidelines set by the Preferred Reporting Items for Systemic Review and MetaAnalysis (PRISMA) standards for systematic reviews of studies that evaluate health care interventions.
Definitions
The ideal value-based intervention should be directed at improving the balance between the quality of health outcomes achieved and the costs to achieve those outcomes. 4 Although we believe that many of the new payment and delivery models were intended to improve value, we thought that it would be difficult to confirm whether or not interventions met this strict definition. Therefore, we defined interventions as alternative payment models or care-delivery models, which we deemed were more accurate descriptions.
We defined alternative payment models as interventions that involved changing the financing of care delivery with an expressed goal of incentivizing improved clinical outcomes as well as reduced utilization and cost of care. Specifically, we defined a bundled payment model as an alternative payment model that replaces traditional FFS with a single payment to providers and/or facilities for all services a beneficiary receives during a predetermined episode of care to treat a given condition, with or without performance accountability. 10 We defined an ACO as an alternative payment model that involves a network of health care providers that share accountability for the cost, quality, and coordination of care to a population of patients who are enrolled in a traditional FFS program with opportunities for shared savings to incentivize improved care coordination. 11 In contrast, we defined a care-delivery model as an intervention that primarily focuses on changing the way care is delivered instead of how care is reimbursed. Specifically, we defined a PCMH as a care-delivery model that adheres to the standards set by the National Committee for Quality Assurance, which include having a physician-led care team to direct disease management, care coordination, a standardized evidence base, patient engagement, and patient education with funding to support care enhancements in addition to traditional payment mechanisms. 12 Finally, we defined interventions in oncology as those that affect patients with a current diagnosis of cancer; interventions that focused on screening only were excluded.
When reporting the impact of each intervention on value in cancer care, we defined value as health outcomes achieved over the costs to achieve those outcomes. For example, if costs or utilization were reduced with no reported effect on outcomes, then the impact would be positive. Similarly, if costs or utilization were increased with no effect on outcomes, then the impact would be negative.
Search Strategy
Because many current alternative payment and care delivery models were designed in response to components of the Affordable Care Act (ACA), the search was limited to articles in the English language that were published after 2010, the year the ACA took effect. We systematically searched PubMed/MEDLINE, EMBASE, CINAHL (the Cumulative Index to Nursing and Allied Health Literature), and the Cochrane Central Register of Controlled Clinical Trials (from January 2010 to March 2017) using terminology that described alternative payment and caredelivery models in cancer care. We included these 4 databases to identify relevant publications from the peerreviewed journal literature, nonpeer-reviewed professional news publications, meeting abstracts, dissertations, and book sections. The final search strategy was developed using a combination of Medical Subject Headings (MeSH) and keyword terms in PubMed/MEDLINE (Table 1) and was adapted for use in the other databases. Additional relevant, references were harvested from the bibliographies of eligible publications.
Study Selection
We used the Endnote X8 reference-management software package (Clairvate Analytics, Philadelphia, PA) to aggregate citations from all search results. All article titles and abstracts were reviewed by 1 investigator (E.M.A. or OR "Incentive Reimbursements" 3 "accountable care organizations"[MeSH] OR "accountable care organizations" OR "accountable care organization" 4 ("compensation" OR "payment" OR "payments" OR "purchasing" OR "reimbursement" OR "reimbursements" OR "spending" OR "funding") AND ("budget-based" OR "value-based" OR "Episode-Based" OR "bundle" OR "bundles" OR "bundled" OR "bundling" OR "Capitation Fee"[MeSH] OR "capitation" OR "capitated" OR "cap" OR "caps") 5 "Alternative payment models" OR "Alternative payment model" OR "Value-Based Purchasing" [ S.M.S.), and all full-text articles were reviewed in duplicate by 2 investigators (E.M.A. and S.M.S.; j 5 0.94) to decide whether to include the article in the review. Studies were eligible for inclusion if they were original reports, described an alternative payment or care-delivery model in cancer, and were conducted in the United States. We excluded studies of interventions that addressed cancer screening alone, those that measured value in the absence of an intervention, those in which the intervention did not have the goal of decreasing costs or improving outcomes, and those that used theoretical models to estimate the potential impact of an alternative payment or caredelivery model. When multiple publications reported redundant outcomes for a given intervention, we included only the most comprehensive article(s). However, if multiple publications reported unique outcomes for a given intervention, then all were included.
Data Extraction
Data extraction was performed by 2 investigators (E.M.A. and S.M.S.) and checked by 1 additional investigator (S.M.), with differences resolved by discussion and consensus. We collected data on study and intervention characteristics, including: first author, intervention name, payer or funder, clinical setting, cancer type(s), intervention type (bundled payment, ACO, PCMH, other), brief description of intervention, publication type, and whether the study was or was not peer-reviewed. For studies that reported results, we collected information on study design, the number of patients included in study and control populations, specific outcomes measured, and results reported. In terms of study design, we defined a pre-post study as a study comparing outcomes in a patient population before and after an intervention. We defined a concurrent-comparator study as a study comparing outcomes in 2 patient groups over the same time horizon, in which only 1 group was exposed to the intervention. Finally, we defined a pre-post with concurrent control study as a study comparing differences between a study population and a control population over the same period before and after an intervention.
Assessment of Study Quality
In studies with results, we examined the quality of evidence using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies (McMaster University, Hamilton, ON), which provides an overall methodological rating of strong, moderate, or weak based on the evaluation of 6 categories: selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts. 13 Quality assessments were performed independently by 2 authors (E.M.A. and S.M.S.), and differences were resolved by discussion and consensus.
Data Analysis
Given the heterogeneity of interventions, study populations, outcome definitions, and the large proportion of interventions without results, we did not pool outcomes in a meta-analysis. Figure 1 illustrates the selection process for the studies included in this systematic review. Our search identified 16,064 articles, and an additional 5 were identified through reference tracking. After removing duplicates, we screened 13,429 titles and abstracts for eligibility and excluded 13,334. Fifty-six articles were excluded during full-text review, and 16 redundant articles were excluded during data abstraction in favor of more comprehensive reports describing the same intervention, leaving 23 studies that described 22 unique alternative payment or caredelivery models in cancer included in the review.
RESULTS
Characteristics and results from the included studies are presented in Table 2. 12,14-35 The 23 articles that met inclusion criteria described 22 unique interventions, including 6 (27%) bundled payments, [14] [15] [16] [17] [18] [19] 4 (18%) ACOs, 20-23 9 (41%) PCMHs, 12,24-32 and 3 (14%) other alternative payment or care-delivery models. [33] [34] [35] The majority of interventions that reported practice setting were implemented in the community (n 5 16 of 21; 76%), and most that reported payer type involved private payers (n 5 13 of 15; 87%). Approximately one-half of the articles (n 5 13; 57%) reported results regarding the impact on value.
Quality of Evidence
Of the 23 articles included, 12 (52%) were published in the peer-reviewed literature, and 13 (57%) published results and thus could be assessed for quality. Table 3 summarizes the quality of evidence assessments conducted on the 13 studies that reported outcomes. 12, 13, [18] [19] [20] [21] [22] [26] [27] [28] [29] [30] 32, 34 Over one-half (n 5 7; 54%) received a weak global rating, and the remaining studies (n 5 6; 46%) received a moderate global rating. No studies evaluating alternative payment or care-delivery models in cancer received a strong global rating.
developed in partnership with private payers. Notably, there was considerable heterogeneity in episode definition. The Blue Cross Blue Shield (BCBS) of Florida radical prostatectomy bundle for early stage prostatectomy was the only bundle that covered exclusively surgical therapy.
14 Two bundles covered radiation therapy: the BCBS of California bundle covered radiation therapy for early stage breast cancer, 16 and the 21st Century Oncology external-beam radiation therapy (EBRT) bundle covered radiation therapy for 13 common cancers with an episode duration of 90 days. 18 The Cancer Treatment Centers of America (CTCA) bundle included services associated with diagnosis and care planning, but excluded treatment services. 15 The United Healthcare (UHC) bundle Review Article included physician hospital care, hospice services, and case management for breast, colon, and lung cancer with chemotherapy medications reimbursed at average sales price and all other physician services reimbursed as FFS. 19 The MD Anderson head and neck bundle included all services associated with the treatment and management of newly diagnosed head and neck cancer for a duration of 12 months, making it the most comprehensive bundle in cancer to date. 17 Only 2 bundled payment interventions reported results. The 21st Oncology EBRT bundle demonstrated improved guideline adherence for patients with bone metastases and prostate cancer but no effect for patients with breast, lung, and skin cancers. 18 Costs were not assessed. The United Healthcare bundle decreased utilization of inpatient hospitalization and therapeutic radiology and paradoxically increased chemotherapy drug costs. 19 Overall, there was a net savings to United Healthcare of $33.36 million.
Accountable Care Organizations
Four studies related to ACOs in cancer care. Two described cancer-specific ACOs, 20,23 and 2 described the impact of general ACO enrollment on the cost and quality of care in Medicare patients with a cancer diagnosis. 21, 22 The 2 cancer-specific ACOs were developed in partnership with private payers; 1 took place in the community setting, 20 and the other took place both at an National Cancer Institute-designated cancer center and within the community. 23 The BCBS of Florida cancerspecific ACO was developed in partnership with Baptist Health South Florida, Advanced Medical Specialties, and Moffitt Cancer Center and focused on "common cancers." 23 Results from this intervention have not yet been published. The Aetna cancer-specific ACO was developed in partnership with US Oncology's Texas affiliate, and results were published after the enrollment of 184 patients who were diagnosed with breast, lung, or colon cancers. 32 A concurrent-comparator study design was used to compare emergency room (ER) visits, inpatient admissions, and length of stay (LOS) between patients in the ACO and all other patients who had newly diagnosed cancer covered by Aetna in Texas. A pre-post design was used to compare costs between ACO-enrolled patients and a cohort of "identical patients" in the year before ACO implementation. ACO enrollment led to approximately 40% fewer ER visits, 16.5% fewer inpatient admissions, and 36% fewer inpatient days for patients; and overall costs were reduced by 10% after the first year. 20 The remaining 2 studies described the impact of patient enrollment in the Medicare Physician Group Practice Demonstration (PGPD) and the Medicare Shared Savings Program (MSSP) ACO on financial and clinical outcomes for patients with cancer and reported mixed results. 21, 22 The Medicare PGPD was a precursor to modern ACOs and represented Medicare's first physician pay-for-performance initiative at the level of the physician group practice. 36 The PGPD study used Medicare FFS claims to compare cancer patients enrolled in the PGPD with local controls before and after PGPD implementation. 21 PGPD enrollment was associated with an annual reduction in Medicare spending of $721 (3.9%) per patient with cancer. Savings were derived entirely from reductions in inpatient stays; and, notably, there were no reductions in cancer-specific procedures or chemotherapy administration. The MSSP ACO study used Medicare claims to compare costs and outcomes associated with major surgical oncology procedures for 9 solidorgan cancers performed at MSSP ACO hospitals versus controls before and after participation in MSSP ACOs. 22 That study reported no difference in perioperative outcomes, including 30 day mortality, readmissions, complications, and inpatient LOS.
Oncology Patient-Centered Medical Homes
We identified 7 unique oncology PCMHs and 2 studies that evaluated the impact of primary care-focused PCMHs on cancer care. Five of the 7 oncology PCMHs took place in community settings, and 1 occurred in mixed settings; 1 PCMH did not report setting information. Four of the oncology PCMHs contracted with private payers, 12, 24, 28, 29 1 contracted with Medicare, 32 1 contracted with mixed payers, 25 and 1 did not report payer type. 31 There were 5 oncology PCMHs that published outcomes, among which the results were mixed. The CareFirst, Maryland-Washington BCBS oncology PCMH had neutral effects on value, with no difference in office visits, average chemotherapy cycles per patient, proportion of patients receiving chemotherapy, and percentage of patients receiving all-generic chemotherapy in a difference-in-difference analysis of 8 intervention practices compared with 7 controls before and after the PCMH was formed. 29 Three analyses demonstrated improved value associated with enrollment in an oncology PCMH. 12, 28, 32 The Michigan Oncology Medical Home, a 4-oncologypractice partnership with Priority Health, documented fewer ER visits, decreased hospitalizations, and an Payment and Care-Delivery Models/Aviki et al Community Oncology Alliance; COME HOME, Community Oncology Medical Home; concurrent comparator, a study that compares outcomes in 2 patient groups over the same time horizon in which only 1 group is exposed to the intervention; CTCA, Cancer Treatment Centers of America; EBRT, external-beam radiation; ER, emergency room; IPU, integrated practice unit; LOS, length of stay; MD Anderson, The University of Texas MD Anderson Cancer Center; MSSP, Medicare Shared Savings Program; NA, not available; NCI, National Cancer Institute; PGPD, Physician Group Practice Demonstration; pre-post, a study that compares outcomes in a patient population before and after an intervention; pre-post with concurrent control, a study that compares differences between a study population and a control population over the same period before and after an intervention; UHC, United Healthcare.
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Review Article estimated savings of $550 per patient. 28 The Consultants in Medical Oncology and Hematology, a 9-clinician oncology practice in Pennsylvania, developed the first oncology PCMH and demonstrated reductions in annual ER visits, hospital admissions, and LOS among patients who received chemotherapy, reporting an aggregate savings of $1 million per physician per year to insurers. 12 The Community Oncology Medical Home (COME HOME) program based in New Mexico Cancer Center and developed by Innovative Oncology Business Solutions (Albuquerque, NM) received a 3-year award from CMS to replicate and scale their oncology medical home to 7 oncology practices across the country. Participating sites reduced ER visits by 23% and inpatient hospitalizations by 28%. 32 Patient satisfaction rates remained greater than 90%.
Two analyses of the impact of primary care-focused PCMHs on cancer care reported that 1 reduced value, 28 whereas the other was value-neutral. 30 Specifically, an analysis of utilization and costs associated with patients who had breast cancer in the North Carolina Medicaid PCMH indicated reduced value through increased monthly outpatient service utilization, no effect on ER visits or hospitalizations, and a $429 per month increase in expenditure for the first 15 months. 27 Notably, this increase in cost was no longer significant at 24 to 36 months postdiagnosis. In a national patient survey that assessed the impact of PCMH access on outcomes for cancer survivors, PCMH access was associated with lower ER visits and prescription medication use but with no effect on outpatient visits, admissions, or total costs. 30 Other Alternative Payment or Care-Delivery Models
We identified 3 alternative payment or care-delivery models in cancer care that could not be categorized as bundles, ACOs, or medical homes. [33] [34] [35] Examples included the Glioma integrated practice unit (IPU), 33 a virtual IPU for the management of patients with glioma; the Diabetes Oncology Program, 34 an integrated care model to enhance coordination of care for patients with cancer who have diabetes; and a year-long, capitated payment for patients with gynecologic malignancies. 35 
DISCUSSION
To our knowledge, this is the most comprehensive review of alternative payment and delivery models in cancer to date. Our systematic review included both peer-reviewed and nonpeer-reviewed literature and identified 22 interventions, including 6 bundled payments, 2 cancerspecific ACOs, 2 nonspecialty-specific ACOs, 7 oncology PCMHs, 2 primary care-focused PCMHs, and 3 noncategorized alternative payment or care-delivery models. Of the 12 interventions that reported results, the majority although this effect was no longer significant at the 2-year to 3-year time-point. Almost all interventions with published results that impacted value focused solely on reducing health care utilization and/or costs of care (n 5 10 of 12; 83%). In contrast, only 2 studies investigated the impact of the intervention on measures of care quality, an important component of the value equation. 4 The 21st Oncology EBRT bundle 18 measured guideline concordance (a process measure), and Herrel et al studied the impact of Medicare ACOs on 30-day mortality and surgical complications. 22 No interventions included an analysis of patient-reported outcomes, although it recently was demonstrated that the collection of these outcomes improves the survival of patients with cancer. 37 The cancer community should not ignore the importance of measuring outcomes as a means to improve value and to ensure that quality of care is not sacrificed at the expense of reducing costs.
Our findings regarding clinical setting and payer/ sponsor also are notable. The majority of interventions were conducted in the community setting (n 5 16 of 21; 76%). Because approximately three-quarters of oncologists practice in nonacademic settings, 38 the testing of alternative payment and care-delivery models in the community promises broad applicability to the larger oncology care-delivery system. In addition, most interventions that reported payer involvement were performed through commercial insurance contracts (n 5 13 of 15; 87%). Our finding of published results for only one-half of interventions (n 5 12; 54%) may be related to a tendency of commercial insurers to keep data proprietary as they compete in the commercial insurer marketplace. The dominance of commercially funded interventions may impede transparency and limit the ability of the broader cancer community to learn from practice innovations that improve value. Commercial insurers and community practices also may be more likely than academics to publish results only for interventions that improve value (ie, publication bias), absent a scholarly mission and an incentive structure that rewards publishing for its own sake. In contrast, results of publicly funded interventions are easily accessed, both because Medicare claims data are publically available and because the CMS often publish their own analyses of projects for public access. Similar transparency and reduced publication bias in the cancer world will be critical for enhancing our understanding. Moving forward, there is reason to expect growth in federal involvement in alternative payment and care-delivery models in cancer, which may lead to increased transparency and reduction in publication bias. In 2016, CMS began piloting the voluntary Oncology Care Model (OCM), an FFS payment model with additional monthly per-member care coordination payments and physician pay-for-performance incentives. 39 Results of the OCM, when available, are likely to be informative.
We observed that large numbers of interventions were described only in the nonpeer-reviewed literature (n 5 10; 45%) and that studies reporting results were of overall poor methodological quality. Selective publication in the nonpeer-reviewed literature may limit the dissemination of information about alternative payment and care-delivery models to clinicians, who may have less exposure to business publications than to medical journals. Independent of peer review, the low quality of evaluations is also of concern. A lack of rigor in evaluations of alternative payment and care-delivery models in cancer may suggest to clinicians that understanding approaches to improving value is less important than understanding other aspects of care. Ultimately, amid calls for greater physician engagement in care value, 40 clinician access to descriptions of alternative payment and care-delivery models and reliable, unbiased estimates of their impact are critical.
The optimal study design for assessing interventions to improve value is not clear. Agreement on a trusted approach to measure the impact of alternative payment and care-delivery models 41 will be critical for efforts to improve value in cancer care. Outside of randomized control trials, which are seldom feasible, the next most rigorous analytical technique to study the impact of a health care intervention is the pre-post study design with a concurrent control. This difference-in-difference technique prevents bias from time-invariant changes in the health care system not attributed to the intervention itself. Large analyses of this type have been performed for alternative payment and care-delivery models outside of cancer, 6, 7, 42 and trust in the quality of these results has provoked meaningful debate about how the health care system should move forward to improve value. 43, 44 We identified 5 examples of alternative payment and care-delivery models in cancer that used variations of this technique 18, 19, 21, 22, 29 and hope that the use of this methodology only increases alongside the implementation of government initiatives like as the OCM.
Our study has several important limitations. First, because of the heterogeneity of intervention type, populations, pilot maturity, and outcome measurement, we were unable to pool data or perform a meta-analysis to estimate the overall impact of alternative payment and caredelivery models in cancer. For example, within bundled payment interventions, episode definitions varied widely, from including comprehensive services 17 to including only services related to diagnosis and care planning. 15 Second, the lack of consistent reporting of results and the poor quality of the literature limited our ability to accurately estimate the effect of individual interventions. However, our inclusion of any type of system-level alternative payment or care-delivery model with any degree of reporting allowed us to present a complete picture of new payment and delivery models affecting the delivery of cancer care. In addition, our careful attention to study quality allowed for transparency and full understanding of the spectrum of literature. Third, our review may have inadvertently excluded ongoing or past alternative payment or care-delivery models in cancer. However, our search of multiple electronic databases and our inclusion of both peer-reviewed and nonpeer-reviewed literature make it unlikely that we missed any large alternative payment or care-delivery model experiments. Finally, we classified intervention types using predefined criteria independent of each intervention's self-identified type. For this reason, our categorizations may differ from the intervention's self-description, but we offer consistency that will facilitate comparisons as the field moves forward.
Conclusion
Despite the growth in alternative payment and delivery models in cancer care since passage of the ACA, our systematic review indicates that there is limited evidence to evaluate their efficacy. Reports of outcomes often are lacking and are of variable quality when available, so the overall efficacy of alternative payment and delivery models in cancer remains unclear. Moving forward, there is a need for both payers and providers to participate in alternative payment and care-delivery models for individuals with cancer and to publish their impact using methodological rigor and standardized reporting of outcomes. Rigorous evaluations and increased transparency will allow for continued innovation in cancer care and the highest possible value for our patients and society.
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